Capri­cor's DMD clin­i­cal tri­al meets pri­ma­ry end­points; Delaware court rules against Take­da in Lupron feud

Bev­er­ly Hills, CA-based biotech Capri­cor Ther­a­peu­tics re­vealed to­day fi­nal da­ta from its clin­i­cal tri­al eval­u­at­ing stem cell ther­a­py CAP-1002 for pa­tients in ad­vanced stages of Duchenne mus­cu­lar dy­s­tro­phy.

Duchenne is a rare mus­cle-wast­ing dis­ease caused by the ab­sence of dy­s­trophin, a pro­tein that helps keep mus­cle cells in­tact. It dis­pro­por­tion­ate­ly af­fects boys — and as of last year, af­fects rough­ly 6,000 in the Unit­ed States.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.